Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LFB Biotechnologies SAS

Division of LFB SA

Latest From LFB Biotechnologies SAS

Coronavirus Update: Searching For A Treatment

Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.

Coronavirus COVID-19 Clinical Trials

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

Coronavirus COVID-19 South Korea

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

Coronavirus COVID-19 Deals

Chronic Lymphocytic Leukemia Market To Grow Despite Biosimilar Wave

The chronic lymphocytic leukemia market is set to increase in size over the next decade despite an anticipated influx of biosimilars, new research by Datamonitor Healthcare finds. AbbVie/J&J's Imbruvica will remain the leading product, but the need for safe and effective therapies for relapsed and refractory CLL patients remains.

Analysis Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Alias(es)
  • LFB Biotechnologies
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • LFB SA
  • Senior Management
  • Contact Info
  • LFB Biotechnologies SAS
    Phone: (33) 69 82 70 10
    3, avenue des Tropiques B.P. 305
    Les Ulis
    Courtabeuf Cedex , 91958